| KMT2C altered in cohorts of …ALTERED_INderived30 of 30show fewer |
|---|
| → altered in cohorts of | Skin Basal Cell Carcinoma 47 / 126 cases (37 %) · ssm · bcc_unige_2016 | — | — | Skin Basal Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Skin Squamous Cell Carcinomasubtype 27 / 83 cases (33 %) · ssm · cscc_ucsf_2021 | — | — | Skin Squamous Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Renal Pelvis and Ureter Urothelial Carcinoma 27 / 119 cases (23 %) · ssm · utuc_msk_2019 · largest of 2 cohorts | — | — | Renal Pelvis and Ureter Urothelial Carcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cervical Squamous Cell Carcinoma 54 / 291 cases (19 %) · ssm · cesc_tcga_pan_can_atlas_2018 · largest of 3 cohorts | — | — | Cervical Squamous Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cutaneous Melanoma 124 / 696 cases (18 %) · ssm · mel_mskimpact_2020 · largest of 3 cohorts | — | — | Cutaneous Melanoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Bladder Urothelial Carcinoma 80 / 474 cases (17 %) · ssm · blca_msk_tcga_2020 · largest of 10 cohorts | — | — | Bladder Urothelial Carcinoma | 10 | Observed | cbioportal | graph → |
| → altered in cohorts of | Melanoma 20 / 122 cases (16 %) · ssm · mel_iatlas_liu_2019 | — | — | Melanoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Non-Small Cell Carcinoma 182 / 1,144 cases (16 %) · ssm · nsclc_tcga_broad_2016 · largest of 3 cohorts | — | — | Lung Non-Small Cell Carcinoma | 3 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Endometrioid Adenocarcinoma 37 / 247 cases (15 %) · ssm · uec_cptac_gdc | — | — | Endometrial Endometrioid Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Squamous Cell Carcinoma 71 / 484 cases (15 %) · ssm · lusc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Lung Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastroesophageal Junction Adenocarcinoma 66 / 518 cases (13 %) · ssm · stes_tcga_pub | — | — | Gastroesophageal Junction Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colon Adenocarcinoma 50 / 429 cases (12 %) · ssm · coad_tcga_gdc · largest of 2 cohorts | — | — | Colon Adenocarcinoma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gastric Adenocarcinoma 55 / 478 cases (12 %) · ssm · stad_tcga · largest of 4 cohorts | — | — | Gastric Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Adenoid Cystic Carcinoma 99 / 1,049 cases (9.4 %) · ssm · acc_2019 | — | — | Adenoid Cystic Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Invasive Breast Carcinoma 357 / 3,879 cases (9.2 %) · ssm · breast_msk_2025 · largest of 9 cohorts | — | — | Invasive Breast Carcinoma | 9 | Observed | cbioportal | graph → |
| → altered in cohorts of | Rectal Adenocarcinoma 605 / 7,237 cases (8.4 %) · ssm · crc_msk_2026 | — | — | Rectal Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Gallbladder Carcinoma 20 / 244 cases (8.2 %) · ssm · gbc_mskcc_2022 | — | — | Gallbladder Carcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Head and Neck Squamous Cell Carcinoma 37 / 515 cases (7.2 %) · ssm · hnsc_tcga_pan_can_atlas_2018 · largest of 4 cohorts | — | — | Head and Neck Squamous Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Cholangiocarcinoma 29 / 417 cases (7.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Prostate Adenocarcinoma 140 / 2,069 cases (6.8 %) · ssm · prad_msk_stopsack_2021 · largest of 10 cohorts | — | — | Prostate Adenocarcinoma | 10 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Glioma 42 / 629 cases (6.7 %) · ssm · difg_glass · largest of 2 cohorts | — | — | Diffuse Glioma | 2 | Observed | cbioportal | graph → |
| → altered in cohorts of | B-Cell Non-Hodgkin Lymphoma 46 / 755 cases (6.1 %) · ssm · mbn_mdacc_2013 | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Colorectal Adenocarcinoma 68 / 1,134 cases (6.0 %) · ssm · crc_msk_2017 · largest of 4 cohorts | — | — | Colorectal Adenocarcinoma | 4 | Observed | cbioportal | graph → |
| → altered in cohorts of | Lung Adenocarcinoma 158 / 2,653 cases (6.0 %) · ssm · luad_mskcc_2023_met_organotropism · largest of 8 cohorts | — | — | Lung Adenocarcinoma | 8 | Observed | cbioportal | graph → |
| → altered in cohorts of | Medulloblastoma 29 / 491 cases (5.9 %) · ssm · mbl_dkfz_2017 | — | — | Medulloblastoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Diffuse Large B-Cell Lymphoma Unclassifiable 56 / 1,001 cases (5.6 %) · ssm · dlbcl_duke_2017 | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Pancreatic Adenocarcinoma 21 / 383 cases (5.5 %) · ssm · paad_qcmg_uq_2016 | — | — | Pancreatic Adenocarcinoma | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Endometrial Carcinoma 96 / 1,882 cases (5.1 %) · ssm · ucec_ancestry_cds_msk_2023 · largest of 7 cohorts | — | — | Endometrial Carcinoma | 7 | Observed | cbioportal | graph → |
| → altered in cohorts of | Myelodysplastic Syndrome 168 / 3,323 cases (5.1 %) · ssm · mds_iwg_2022 | — | — | Myelodysplastic Syndrome | 1 | Observed | cbioportal | graph → |
| → altered in cohorts of | Hepatocellular Carcinoma 69 / 1,370 cases (5.0 %) · ssm · hcc_msk_2024 · largest of 2 cohorts | — | — | Hepatocellular Carcinoma | 2 | Observed | cbioportal | graph → |